The physiological disposition of p-octopamine in man

Hengstmann, Jürgen H.; Konen, Wolfgang; Konen, C.; Eichelbaum, Michel; Dengler, H. J.

doi:10.1007/bf00500148

Cited by 22 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4-(2-Amino-1-hydroxyethyl)phenol (octopamine) is a biogenic amine and a metabolite of tyramine, which is well established endogeneous invertebrates neuromodulator [1]. Since the discovery of various subclasses of trace amine associated receptors (TAARs), the studies of octopamine were extended on human physiology and pathophysiology [2].…”

Section: Introductionmentioning

confidence: 99%

Separation of octopamine racemate on (R,S)-2-amino-1-phenylethanol imprinted polymer – Experimental and computational studies

Sobiech

Żołek

Luliński

et al. 2016

Talanta

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Separation of octopamine racemate on (R,S)-2-amino-1-phenylethanol imprinted polymer – Experimental and computational studies

Sobiech

Żołek

Luliński

et al. 2016

Talanta

View full text Add to dashboard Cite

“…An important parameter for estimating in vivo exposure is maximum plasma concentration. Available clinical data on DMAA, [17] amphetamine, [18] methamphetamine, [18] phentermine, [19] phenylephrine, [20] and octopamine [21] all indicated similar maximum plasma concentrations around 1 μM. Therefore, in the current study, compounds exhibiting IC 50 > 100 μM were defined as relatively weak inhibitors, since these values are over 100-fold higher than known plasma concentrations for several amine stimulants.…”

Section: Resultsmentioning

confidence: 66%

Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements

Liu

Santillo

2015

Drug Testing and Analysis

View full text Add to dashboard Cite

A number of dietary supplements used for weight loss and athletic performance enhancement have been recently shown to contain a variety of stimulants, for which there is a lack of pharmacological and toxicological information. One concern for these emerging compounds is their potential to inhibit metabolic enzymes in the liver such as cytochromes P450 (CYP), which can lead to unexpected interactions among dietary supplements, drugs, and other xenobiotics. In this study, inhibition of human recombinant CYP2D6 and CYP3A4 by 27 amine stimulants associated with dietary supplements and their analogs was evaluated by luminescence assays. The strongest CYP2D6 inhibitors were coclaurine (IC50 = 0.14 ± 0.01 μM) and N-benzylphenethylamine (IC50 = 0.7 ± 0.2 μM), followed by several other relatively strong inhibitors (IC50 , 2-12 μM) including β-methylphenethylamine, N,β-dimethylphenethylamine (phenpromethamine), 1,3-dimethylamylamine (DMAA), N,α-diethylphenethylamine, higenamine (norcoclaurine) and N,N-diethylphenethylamine. Only nine compounds inhibited CYP3A4 by 20-55% at 100 μM. Results of this study illustrate that several amine stimulants associated with dietary supplements inhibit CYP2D6 and CYP3A4 in vitro, and these compounds may participate in adverse drug-dietary supplement interactions in vivo. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

“…Within the first 24 h post administration, approximately 20% of the therapeutic synephrine dose and 30% of the therapeutic octopamine dose were renally excreted as intact and/or conjugated compounds (data not shown), which is in agreement with literature data (Hengstmann and Aulepp, ; Hengstmann et al , ). In case of the nutritional supplements, between 37 and 42% of the administered synephrine was determined; owing to the low concentrations, however, interference by biosynthetic endogenous synephrine cannot be excluded.…”

Section: Resultsmentioning

confidence: 99%

“…1, 1) and analogous compounds (including, for example, m-and o-octopamine as well as the N-methylated derivatives referred to as synephrine, Fig. 1, 2) have since been subject of numerous animal and human studies concerning their natural presence in tissues and body fluids (Pisano et al, 1960;Williams et al, 1987), biosynthetic pathways (Axelrod and Saavedra, 1977;Boulton and Davis, 1987;Brandau and Axelrod, 1972;Breese et al, 1969;Williams et al, 1987), routes of elimination (Hengstmann et al, 1974(Hengstmann et al, , 1975, and potential roles as therapeutic agents (Kuske, 1969;Stucke, 1972;Stur, 1971). Particular attention was focused on the effects of octopamine and synephrine on aand b-adrenoceptors concerning lipolysis, glucose transport, and amine oxidation in mammalian fat cells (Brown et al, 1988;Carpene et al, 1999;Fontana et al, 2000;Visentin et al, 2001), and synephrine alkaloids have generally been investigated and discussed with regard to their possible application in obesity treatments (Fugh-Berman and Myers, 2004;Haaz et al, 2006;Kubo et al, 2005).…”

Section: Introductionmentioning

confidence: 99%

Analysis of octopamine in human doping control samples

Thevis

Koch

Sigmund

et al. 2011

Biomedical Chromatography

View full text Add to dashboard Cite

The biogenic amine octopamine [4-(2-amino-1-hydroxyethyl)phenol] is prohibited in sports owing to its stimulating and performance-enhancing properties. Adverse analytical findings in athletes' doping control samples commonly result from surreptitious applications; however, the occurrence of octopamine in nutritional supplements and in selected invertebrates as well as the assumption that its N-methylated analog synephrine [4-(1-hydroxyethyl-2-methylamino)phenol, not banned by anti-doping authorities but currently monitored in prevalence studies) might be converted in-vivo into octopamine have necessitated a study to investigate the elimination of synephrine and octopamine present in over-the-counter products. Urine samples collected after administration of nutritional supplements containing octopamine and/or synephrine as well as urine samples collected after therapeutic application of octopamine- or synephrine-containing drugs were analyzed using a validated solid-phase extraction-based procedure employing a weak cation exchange resin and liquid chromatographic/tandem mass spectrometric detection with electrospray ionization and multiple reaction monitoring. In the case of therapeutic octopamine application, the urinary concentration of the target compound increased from baseline levels below the lower limit of detection to 142 µg/mL, while urine samples collected after synephrine as well as dietary supplement administration did not yield any evidence for elevated renal excretion of octopamine.

show abstract

The physiological disposition of p-octopamine in man

Cited by 22 publications

References 11 publications

Separation of octopamine racemate on (R,S)-2-amino-1-phenylethanol imprinted polymer – Experimental and computational studies

Separation of octopamine racemate on (R,S)-2-amino-1-phenylethanol imprinted polymer – Experimental and computational studies

Cytochrome P450 2D6 and 3A4 enzyme inhibition by amine stimulants in dietary supplements

Analysis of octopamine in human doping control samples

Contact Info

Product

Resources

About